An aerosol delivery device includes at least one housing, a heating element, a sensor, and a microprocessor coupled to the heating element and the sensor. The at least one housing encloses a reservoir configured to retain an aerosol precursor composition. The sensor is configured to produce measurements of differential pressure between an ambient atmospheric pressure and a pressure caused by airflow through at least a portion of the aerosol delivery device. The sensor is also configured to convert the measurements of differential pressure to corresponding electrical signals. The microprocessor is configured to receive the corresponding electrical signals and operate in an active mode only in an instance in which the differential pressure is at least a threshold differential pressure. The microprocessor in the active mode is configured to control the heating element to activate and vaporize components of the aerosol precursor composition.

A nebulizer device for administering aerosol cannabinoid mixtures to a user includes a mouthpiece, a first reservoir, a second reservoir, and a nebulizer device. The nebulizer module is configured to receive a first dosage of the first liquid from the first reservoir and a second dosage of a second liquid from the second reservoir. The nebulizer module is also configured to transform the first liquid into an inhalant and the second liquid into an aerosol that are provided to the user through the mouthpiece. The device further includes a dosage module configured to independently control the delivery of the first liquid and the second liquid to the nebulizer module to set a ratio between the first dosage of the first liquid and the second dosage of the second liquid. The dosage module thereby controls a composition of an aerosol cannabinoid mixture administered to the user.

A method of flowing a medicament containing powder using gas, including, providing a volume of a gas according to one or more release conditions; directing flow of said gas through or adjacent a powder including a medicament; and releasing a therapeutically effective amount of said powder using said gas. Optionally, the releasing comprises releasing according to breath considerations. Optionally or alternatively, the releasing comprises releasing according to time considerations. In an exemplary embodiment of the invention, the powder is held in a capsule that has apertures formed therein.

The present invention discloses an ultrasonic atomizer and electronic cigarette. The ultrasonic atomizer comprises an atomization piece and a liquid guide structure, which guides liquid onto an upper surface of the atomization piece; the liquid guide structure communicates with a liquid storage cavity; the upper surface of the atomization piece communicates with an airflow passage; and the atomization piece comprises a piezoelectric ceramic layer and an electric conductor, which drives vibration of the piezoelectric ceramic layer. No micropore needs to be provided in the atomization piece of the present invention to eject the atomized gas, thereby being free of the situation that the micropore is blocked by larger atomized gas particles, resulting in that the atomized gas cannot be ejected, and meanwhile the situation of liquid leakage of the atomizer can be better prevented.

A method and device for delivering a pharmaceutical to the airway of a human or animal patient, in one aspect, includes a dose drum formed into a cylinder and including a plurality of dose compartments for containing individual doses. In another aspect, the device may include a reservoir containing a pharmaceutical material in bulk form and a metering recess for metering the pharmaceutical material to form a pharmaceutical dose. Another aspect provides an inhaler with a combined reservoir and dosing chamber configured to contain multiple doses of a pharmaceutical material.

The present invention relates to therapeutic methods of administering tiotropium using a nebulizer. The present invention also relates to methods of treating inflammatory or obstructive airway diseases by administering a sterile nebulizable composition of tiotropium using a nebulizer.

A medicament delivery device comprises a dosing chamber configured to contain dry powder medicament, a transducer and a controller electrically coupled to the transducer. The medicament delivery device is capable of delivering a therapeutically effective dose of dry powder medicament in response to between 2-20 tidal inhalations, the dose preferably having a mass median aerodynamic diameter (MMAD) of about 6 microns or less and a fine particle fraction of at least 30%.

Devices, systems and methods are provided for delivering coffee-derived volatiles to a user, particularly for the treatment of addiction. The coffee volatiles are selected and delivered by devices and systems which allow for concentrated delivery to the olfactory system of the user in a controlled manner. The olfactory system is the part of the sensory system used for smelling or olfaction. Olfaction of such coffee volatiles in this prescribed fashion stimulates the reward system of the brain such that a specific desired outcome is achieved. In some embodiments, the desired outcome is a reduction in addiction symptoms or curbing of a sensation of addiction withdrawal.

The invention provides an inhalation device using an electrically driven vibratory element for releasing a drug dose into a flow channel, and a controller for activating/deactivating the vibratory element. A sensor arrangement is able to differentiate between inhalation flow and exhalation flow through the flow channel, to assist in forming a model of the breathing pattern of the user. The device can detect reliably inhalation flow patterns from patients of all ages.

An electrically-powered inhalation device for delivery of an aerosol to the oropharynx of a user includes a distal portion housing a piezo assembly including an ultrasonically vibrable mesh membrane, and a neck portion including a narrow section characterized by a minimum cross-sectional dimension that is at least 10% smaller than a minimum cross-sectional dimension of the distal portion passing through and parallel to the mesh membrane. At least a part of the narrow section is displaced proximally from the mesh membrane by at least 0.5 cm and not more than 6 cm. The inhalation device is shaped such that when the user's lips and/or teeth are transversely engaged with the narrow section, the mist-generating location resides distal to the user's teeth within the user's oral cavity and the mist-exiting location is in direct fluid communication with the user's oropharynx.